Cellular therapy of cancer with natural killer cells-where do we stand?

Cytotherapy

Volumn 15, Issue 10, 2013, Pages 1185-1194

  Klingemann, Hans G ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CD3 ANTIGEN; CD56 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CHIMERIC PROTEIN; CYCLOPHOSPHAMIDE; DASATINIB; DEXAMETHASONE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; INTERFERON; INTERLEUKIN 15; INTERLEUKIN 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LENALIDOMIDE; LYMPHOCYTE ANTIGEN RECEPTOR; PENTOSTATIN; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; SORAFENIB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL EXPANSION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MEGADOSE; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; KIDNEY CANCER; LEUKEMIA REMISSION; LYMPHOMA; MELANOMA; NATURAL KILLER CELL; NONHUMAN; OVARY CANCER; PERTHES DISEASE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE DRUG DOSE; T CELL DEPLETION; THYROIDITIS; WHOLE BODY RADIATION;

ANIMALS; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; GENETIC THERAPY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84883212394     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.03.011     Document Type: Review

References (105)

1. Kantoff P.W., Higano C.S., Shore N.D., Berger R., Small E.J., Penson D.F., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. NEngl J Med 2010, 363:411-422. IMPACT Study Investigators.
2. Uccelli A., Moretta L. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008, 8:726-736.
3. Horwitz E.M., Maziarz R.T., Kebriaei P. MSCs in hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011, 17:S21-S29.
4. Aversa F., Tabilio A., Velardi A., Cunningham I., Terenzi A., Falzetti F., et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. NEngl J Med 1998, 339:1186-1193.
5. Dazzi F., Szydlo R.M., Craddock C., Cross N.C., Kaeda J., Chase A., et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000, 95:67-71.
6. Zitvogel L., Tesniere A., Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006, 6:715-727.
7. Xing D., Ramsay A.G., Decker W., Lee D.A., Robinson S., Shah N., et al. CD137L reverse the immunological synapse defects of natural killer cells in acute myeloid leukemia. Blood 2011, 118a:246.
8. Jena B., Dotti G., Cooper L.J.N. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010, 116:1035-1044.
9. Kochendoerfer J.N., Wilson W.H., Janik J.E., Dudley M.E., Stetler-Stevenson M., Feldman S.A., et al. Eradication of B-lineage cells and regression of lymphoma in apatient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116:4099-4102.
10. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. NEngl J Med 2011, 365:725-733.
11. Verheyden S., Demanet C. NK cell receptors and their ligands in leukemia. Leukemia 2008, 22:249-257.
12. Lanier L.L. Up on the tightrope: natural killer cell activation and inhibiton. Nat Immunol 2008, 9:495-502.
13. Vivier E., Raulet D.H., Moretta A., Caligiuri M.A., Zitvogel L., Lanier L.L., et al. Innate or adaptive immunity? The example of natural killer activating ligands on myeloid cells. Science 2011, 331:44-49.
14. Anfossi N., Andre P., Guia S., Falk C.S., Roetynck S., Stewart C.A., et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006, 25:331-342.
15. Raulet D.H., Vance R.E. Self tolerance of natural killer cells. Nature Rev Immunol 2006, 6:520-531.
16. Kim S., Poursine-Laurent J., Truscott S.M., Lybarger L., Song Y.-J., Yang L., et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005, 436:711-714.
17. Gill A.I., Vasey A.E., Baker J.B., Smith A., Kohrt H.E., Florek M., et al. Natural killer cell adoptive immunotherapy is hampered by a rapid development of NK cell dysfunction characterized by loss of effector mechanisms and downregulation of the transcription factors T-bet and ecomesodermin; definition and possible mechanism of NK cell exhaustion. Blood 2012, 119:5758-5768.
18. Helmlinger G.F., Yuan M., Dellian M., Jaia R.K. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997, 3:177-182.
19. Parkhurst M.R., Riley J.R., Dudley M.E., Rosenberg S.A. Adoptively transferred autologous natural killer cells persist in circulation but do not mediate tumor regression. Clin Canc Res 2011, 17:6287-6297.
20. Krause S.W., Gastpar R., Andresen R., Gross C., Ullrich H., Thonigs G., et al. Treatment of colon cancer patients with ex vivo heat shock protein 70 peptide-activated, autologous natural killer cells: a clinical phase I trial. Clin Cancer Res 2004, 10:3699-3707.
21. Motohashi S., Ishikawa A., Ishikawa E., Otsuji M., Iizasa T., Haoaka H., et al. Aphase I study of ex vivo expanded natural killer T cells in patients with advanced and recurrent non-small lung cancer. Clin Cancer Res 2006, 12:6079-6086.
22. Koepsell S.A., Miller J.S., McKenna D.H. Natural killer cells: a review of manufacturing and clinical utility. Transfusion 2013, 53:404-410.
23. McKenna D.H., Sumstad D., Bostrom N., Kadidlo D.M., Fautsch S., McNearney S., et al. Good manufacturing practices production of natural killer cells for immunotherapy: a six year single-institution experience. Transfusion 2007, 47:520-528.
24. Iyengar R., Handgretinger R., Babarin-Dorner A. Purification of human natural killer cells using a clinical-scale immunomagnetic method. Cytotherapy 2003, 5:479-484.
25. Miller J.S., Oelkers S., Verfaillie C., McGlave P. Role of monocytes in the expansion of human activated natural killer cells. Blood 1992, 80:2221-2229.
26. Geller M.A., Cooley S., Judson P.L., Ghebre R., Carson L.F., Argenta P.A., et al. Aphase II study of allogeneic natural killer celltherapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011, 13:98-107.
27. Lee H.J., Gulbis A., De Padua Silva L., Hosing C., Khouri I., deLima M., et al. Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT. Bone Marrow Transplant 2008, 42:67-69.
28. Sutlu T., Stellan B., Gilljam M., Concha Quezada H., Nahi H., Gahrton G., Alici E. Clinical-grade, large scale, feeder free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy 2010, 12:1044-1055.
29. Carlens S., Gilljam M., Chambers B.J., Aschan J., Guven H., Ljunggre H.G., et al. Anew method for in vitro expansion of cytotoxic human CD3-56+ natural killer cells. Hum Immunol 2001, 62:1092-1098.
30. Alici E., Sutlu T., Bjoerstrand B., Gilljam M., Tellan B., Nahi H., et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 2008, 111:3155-3162.
31. Fujisaki H., Kakuda H., Shimasaki N., Imai C., Ma J., Lockey, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009, 69:4010-4017.
32. Berg M., Lundqvist, McCoy P., Samsel L., Fan Y., Tawab A., et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009, 11:343-357.
33. Boissel L., Tuncer H.H., Betancur M., Wolfberg A., Klingemann H. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells. Biol Blood Marrow Transplant 2008, 14:1031-1038.
34. Spanholtz J., Preijers F., Tordoir M., et al. Generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PloS One 2011, 6:e20740.
35. Lapteva N., Durett A.G., Sun J., Rollins L., Dandekar V., Mei Z., et al. Large-scale ex vivo expansion and characterization of natural killer cells for clinical application. Cytotherapy 2012, 14:1131-1143.
36. Fujisaki H., Kakuda H., Imai C., Mullighan C.G., Campana D. Replicative potential of human natural killer cells. Br J Haematol 2009, 145:606-613.
37. Perussia B., Ramoni C., Anegon I., Cuturi M.C., Faust J., Trinchieri G. Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B-lymphoblastoid cell lines. Nat Immun Cell Growth Regul 1987, 6:171-188.
38. Woll P.S., Grzywacz B., Tian X., Marcus R.K., Knorr D.A., Verneris M.R., et al. Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with highly potent in vivo anti-tumor activity. Blood 2009, 113:6094-6101.
39. Suck G. Novel approaches using natural killer cells in cancer therapy. Semin Cancer Biol 2006, 16:412-418.
40. Klingemann H-G. Development and testing of NK cell lines. In: Lotze MT, Thompson AW (eds). Natural Killer Cells: Basic Science and Clinical Applications. Elsevier. 2010:169-75.
41. Gong J., Maki G., Klingemann H. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994, 8:652-658.
42. Tam Y.K., Miyagawa B., Ho V.C., Klingemann H.-G. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. JHematother 1999, 8:281-290.
43. Yan Y., Steinherz P., Klingemann H.G., Dennig D., Childs B.H., McGuirk J., O'Reilly R.J. Antileukemia activity of a natural killer cell line against human leukemias. Clin Cancer Res 1998, 4:2859-2868.
44. Swift B.E., Williams B.A., Kosaka Y., Wang X.-H., Medin J.A., Viswanathan S., et al. Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. Haematologica 2012, 97:1020-1028.
45. Maki G., Klingemann H.G., Martinson J.A., Tam Y.K. Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. JHematother Stem Cell Res 2001, 10:369-383.
46. Tam Y., Martinson J.A., Doligosa K., Klingemann H.-G. Ex vivo expansion of the highly cytotoxic human NK-92 cell line under cGMP conditions for clinical adoptive cellular immunotherapy. Cytotherapy 2003, 5:259-272.
47. Arai S., Meagher R., Swearingen M., et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 2008, 10:625-632.
48. Tonn T., Becker S., Esser R., Schwabe D., Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. JHematother Stem Cell Res 2001, 10:535-544.
49. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., McNearney S.A., Yun Gong H., Fautsch S.K., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
50. Smyth M.J., Teng M.W., Swann J., Kyparissoudis K., Godfrey D.I., Hayakawa Y. CD4+CD25+ T-regulatory cells suppress NK cell-mediated immunotherapy of cancer. JImmunol 2006, 176:1582-1587.
51. Lopez R., Sellers S., Dunbar C.E., Childs R. IL-15 administration to in-vivo expand adoptively transferred NK cells in rhesus macaques. Blood 2010, 116:960. [abstract].
52. Klebanoff C.A., Khong H.T., Antony P.A., Palmer D.C., Restifo N.P. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor Immunotherapy. Trends Immunol 2005, 26:111-117.
53. Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. JClin Oncol 2008, 26:5233-5239.
54. Tanaka J., Sugita J., Shiratori S., Shigematsu A., Imamura M. Dasatinib enhances the expansion of CD56+CD3- NK cells from blood. Blood 2012, 119:6175-6176.
55. Borg C., Terme M., Taieb J., Menard C., Flament C., Robert C., et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. JClin Invest 2004, 114:379-388.
56. Skov S., Terndrup Pedersen M., Andresen L., Straten P.T., Woetmann A., Ødum N. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I related chain A and B. Cancer Res 2005, 65:11136-11145.
57. Khuu H., Betters D.M., Cook L. Adoptive transfer of escalating doses of ex vivo expanded autologous natural killer (NK) cells in patients with advanced malignancies following bortezomib treatment to sensitize to NK-TRAIL cytotoxicity. Blood 2010, 116:4296. [abstract].
58. Bellucci R., Nguyen H.-N., Martin A., Heinrichs S., Schinzel A.C., Hahn W.C., et al. Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells. JClin Invest 2012, 122:2369-2383.
59. Hsu A.K., Quach H., Tai T., Prince H.M., Harrison S.J., Trapani J.A., et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011, 117:1605-1613.
60. Wu L., Adams M., Carter T., Chen R., Muller G., Stirling D., et al. Lenalidomide enhances natural-killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Cancer Immunol Immunother 2011, 60:61-73.
61. Krusch M., Salih J., Schlicke M., Baessler T., Kampa K.M., Mayer F., et al. The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. JImmunol 2009, 183:8286-8294.
62. Ramos C., Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther 2011, 11:855-873.
63. Sadelain M., Brentjens R., Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009, 21:215-223.
64. Brentjens R., Yeh R., Bernal Y., Riviere I., Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T-cells: case report of an unforeseen adverse event on a phase I clinical trial. Mol Ther 2010, 18:66-68.
65. Morgan R.A., Yang J.C., Kitano M., Dudley M.E., Laurencot C.M., Rosenberg S.A. Serious adverse event following the administration of T-cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010, 18:843-851.
66. Rosenberg SA. A fatal "cytokine" storm within hours of adoptive transfer of Her2-CAR T-cells. 12-1-2009. Recombinant DNA Advisory Committee (RAC) meeting. Available at: mailto:http://oba.od.nih.gov/rdna/rac_past_meeting_2009_webcast.html#dec09.
67. Terme M., Ullrich E., Delahaye N.F., Chaput N., Zitvogel L. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol 2008, 9:486-494.
68. Salagianni M., Baxevanis C.N., Papamichail M., Perez S.A. New insights into the role of NK cells in cancer immunotherapy. Oncoimmunology 2012, 1:205-207.
69. Guven H., Konstantinidis K.V., Alici E., Aints A., Abedi-Valugerdi M., Christensson B., et al. Efficient gene transfer into primary human natural killer cells by retroviral transduction. Exp Hematol 2005, 33:1320-1328.
70. Imai C., Iwamoto S., Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005, 106:376-383.
71. Su S., Betters D.M., Ramanathan M., Keyvanfar K., Smith A., Feng X., et al. Optimizing lentiviral transduction of human natural killer cells. Blood 2011, 118:4714.
72. Boissel L., Betancur M., Lu W., Wels W.S., Marino T., Van Etten R.A., et al. Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens. Leuk Lymphoma 2012, 53:958-965.
73. Li L., Liu N., Feller S., Allen C., Shivakumar R., Fratantoni J., et al. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method mRNA transfection of chimeric receptors in NK cells. Cancer Gene Ther 2010, 17:147-154.
74. Boissel L., Betancur M., Wels W.S., Tuncer H., Klingemann H. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res 2009, 33:1255-1259.
75. Romanski A., Uherek C., Bug G., Muller T., Rossig C., Kampfmann M., et al. Re-targeting of an NK cell line (NK-92) with specificity for CD19 efficiently kills human B-precursor leukemic cells. Blood 2004, 104:751. [abstract].
76. Uherek C., Tonn T., Uherek B., Becker S., Schnierle B., Klingemann H., et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 2002, 100:1265-1273.
77. Mueller T., Uherek C., Maki G., Chow K.U., Klingemann H.-G., Tonn T., et al. Expression of a CD20 specific chimeric antigenreceptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of leukemia and lymphoma cells. Cancer Immunol Immunother 2008, 57:411-423.
78. Shimasaki N., Fujisaki H., Cho D., Masselli M., Lockey T., Eldridge P., et al. Aclinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy 2012, 14:830-840.
79. Esser R., Mueller T., Stefes D., Kloess S., Seidel D., Gillies S.D., et al. NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC like activity against tumor cells of neuroectodermal origin. JCell Mol Med 2012, 16:569-581.
80. Sahm C., Schoenfeld K., Wels W.S. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol Immunother 2012, 61:1451-1461.
81. Tassev D.V., Cheng M., Cheung N.K. Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor. Cancer Gene Ther 2012, 19:84-100.
82. Weitzman J., Boissel L., Rabinovitz A., Klein A., Klingemann H. Variable contribution of monoclonal antibodies to ADCC in CLL patients. Leuk Lymphoma 2009, 26:1-8.
83. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood 2002, 99:754-758.
84. Treon S.P., Hansen M., Branagan A.R., Verselis S., Emmanouilides C., Kimby E., et al. Polymorphisms in FcgRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. JClin Oncol 2005, 23:474-481.
85. Rosenberg S.A., Lotze M.T., Muul L.M., Leitman S., Chang A.E., Ettinghausen S.E., et al. Observations onthe systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. NEngl J Med 1985, 313:1485-1492.
86. Lundqvist A., Berg M., Smith A., Cook L., Goodwin R., Ramos C., et al. Adoptive Infusion of ex-vivo expanded autologous natural killer (NK) cells in cancer patients treated with bortezomib to sensitize to NK-TRAIL cytotoxicity. Blood 2010, 114:4080. [abstract].
87. Ruggeri L., Campanni M., Casucci M., Volpi I., Tosti A., Perruccio K., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999, 94:333-339.
88. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
89. Farag S.S., Bacigalupo A., Eapen M., Bacigalupo A., Eapen M., Hurley C., et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant 2006, 12:876-884.
90. Davies S.M., Ruggieri L., DeFor T., Wagner J.E., Weisdorf D.J., Miller J.S., et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Blood 2002, 100:3825-3827.
91. Bornhauser M., Schwerdtfeger R., Martin H., Frank K.H., Theuser C., Ehninger G. Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 2004, 103:2860-2861.
92. Cooley S., Weisdorf D.J., Guethlein L.A., Klein J., Wang T., Le C.T., et al. Donor selection for natural killer cell receptorgenes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010, 116:2411-2419.
93. Vey N., Bourhis J.-H., Boissel N., Bordessoule D., Prebet T., Charbonnier A., et al. Aphase 1 trial of the anti-inhibitor KIR mAb IPH2101 for AML in complete remission. Blood 2012, 120:4317-4323.
94. Benson D.M., Hofmeister C.C., Padmanabhan S., Suvannasankha A., Jagannath S., Abonour R., et al. Aphase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/referactory multiple myeloma. Blood 2012, 120:4324-4333.
95. Ruggeri L., Mancusi A., Capanni A., Urbani E., Carotti A., Aloisi T., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007, 110:433-440.
96. Rubnitz J.E., Inaba H., Ribeiro R.C., Pounds S., Rooney B., Bell T., et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. JClin Oncol 2010, 28:955-959.
97. Reed W., Noga S.J., Gee A.P., Rooney C.M., Wagner J.E., McCullough J., McKenna D.H., et al. Production Assistance for Cellular Therapies (PACT): four-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapies. Transfusion 2009, 49:786-796.
98. Klingemann H., Grodman C., Cutler E., Duque M., Kadidlo D., Klein A., et al. Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell enriched infusions. Transfusion 2013, 53:412-418.
99. Koepsell S., Kadidlo D., Fautsch S., McCullough J., Klingemann H., Wagner J., et al. Successful "in-flight" activation of natural killer cells during long-distance shipping. Transfusion 2013, 53:398-403.
100. Hummon D., Zantek N.D., Sumstad D., Miller J.S., McKenna D.H. Transfusion-associated graft versus host disease: a perspective from a cell therapy laboratory. Transfusion 2009, 49:1028-1029.
101. Stern M., Passweg J.R., Meyer-Monard S., Esser R., Tonn T., Soerensen J., et al. Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. Bone Marrow Transplant 2013, 48:433-438.
102. Rizzeri D.A., Storms R., Chen D.-F., Long G., Yang Y., Nikcevich D.A., et al. Natural killer cell-enriched donor lymphocyte infusions from a 3-6/6 HLA matched family member following non-myeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010, 16:1107-1114.
103. Tam Y.K., Maki G., Miyagawa B., Hennemann B., Tonn T., Klingemann H.-G. Characterization of genetically altered, interleukin 2 independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum Gene Ther 1999, 10:1359-1373.
104. Binyamin L., Alpaugh R.K., Hughes T.L., Lutz C.T., Campell K.S., Weiner L.M. Blocking NK cell inhibitory self-recognition promotes antibody dependent celluar cytotoxicity in a model of anti-lymphoma therapy. JImmunol 2008, 180:6392-6401.
105. Klinger M., Brandl C., Zugmaier G., Hijazi Y., Bargou R.C., Topp M.S., et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012, 119:6226-6233.